18新利官网|18luck新利官网

Skip to content AboutNews/In the MediaSiteman Cancer Center ranked No. 10 among U.S. cancer centersSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine has been named No. 10 among cancer centers nationally by U.S. News & World Report. The recognition is part of the overall ranking&＃8230;Read The Full Story Mission, Vision &＃038; History Why Siteman Diversity, Equity &＃038; Inclusion at SitemanAboutDiversity, Equity &＃038; Inclusion at SitemanLearn More Leadership Organizations Committees Partnerships Contact This is Cancer Learning With National Leaders In the News TreatmentClinicalHow Siteman is leading the way in personalized brain tumor treatmentIf you or a loved one have recently been diagnosed with a brain tumor, you likely feel a great deal of fear and have many questions. The brain is the epicenter of who we are,&＃8230;Read The Full Story Physician Directory Clinical Trials Search Patient Experience Siteman Psychology Service Survivorship Cardio-Oncology Lymphedema Surgery NCI Cancer Information A to Z Treatment Roles Cancer Types Bladder Brain Breast Cervical Childhood Cancers Colorectal Young Onset Colorectal Esophageal Gallbladder Head/Neck Kidney Leukemia Liver Lung Lymphoma Multiple Myeloma Myelodysplastic Syndromes (MDS) Ovarian Pancreatic Prostate Sarcoma/Rare Tumors Skin Stomach Testicular Thyroid Uterine The Siteman Approach Medical Therapy Expertise in Radiation Oncology Surgery Genetics and Hereditary Cancer Cancer Imaging Immunology and Immunotherapy Pathology Patient and Family Services Specialized Programs Stem Cell Transplant and Cellular Therapies Center Gynecologic Oncology Brain Tumor Center Sarcoma VisitingNews/In the MediaSiteman Cancer Center expands proton therapy treatmentSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is expanding proton therapy for patients by adding the latest, most innovative technology to its S. Lee Kling Proton Therapy Center with the addition of&＃8230;Read The Full Story Patient and Family Services Washington University Medical Campus West County St. Charles County South County Siteman Kids at St. Louis Children’s Hospital North County Illinois Siteman Cancer Network Cancer Care Clinic Barnard Health and Cancer Information Center Pharmacies Payment Information &＃038; Assistance Patient Rights Patient Privacy PreventionPreventionSiteman explains what every woman should know about endometrial cancer risk, symptoms and screeningEndometrial cancer is the fourth most common cancer for women in the United States. It also accounts for approximately 4 percent of cancer deaths in women. However, because it is usually diagnosed early, it is&＃8230;Read The Full Story Your Disease Risk® Preventing Cancer Risk Factors Screening Smoking Cessation Mammography Genetic Counseling Cancer News in Context 8IGHTWAYS® to Prevent Cancer Health Disparities Community Outreach and Engagement ResearchResearchImmunity boosting treatment enhances CAR-T cell therapy for blood cancersAdvances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration&＃8230;Read The Full Story List of Researchers Significant Research Advances Learn About Clinical Trials Membership Information Plan to Enhance Diversity (PED) Research Programs Funding Opportunities Training &＃038; Education Shared Resources (Cores) Resources for Researchers SPORE in Pancreatic Cancer SPORE in Endometrial Cancer SPORE in Leukemia Center for Genome Integrity CliniciansNews/In the Media$5.3 million grant supports research into lung cancer recurrenceResearchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after&＃8230;Read The Full Story Physician Services Educational Programs GiveNews/In the MediaCouple honors physician with gift for distinguished professorshipEndowment will support leader in gynecologic oncology Financial adviser Elizabeth Mannen Berges lives each day with heightened gratitude for the basic components of a meaningful life—fulfilling work, caring relationships, and a sense of purpose. A&＃8230;Read The Full Story Siteman Advancement Office Volunteering and Contributing The Foundation for Barnes-Jewish Hospital AboutNews/In the MediaSiteman Cancer Center ranked No. 10 among U.S. cancer centersSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine has been named No. 10 among cancer centers nationally by U.S. News & World Report. The recognition is part of the overall ranking...Read The Full StoryAboutNews/In the MediaSiteman Cancer Center ranked No. 10 among U.S. cancer centersSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine has been named No. 10 among cancer centers nationally by U.S. News & World Report. The recognition is part of the overall ranking...Read The Full StoryMission, Vision & HistoryWhy SitemanDiversity, Equity &＃038; Inclusion at SitemanAboutDiversity, Equity &＃038; Inclusion at SitemanLearn MoreLeadershipOrganizationsCommitteesPartnershipsContactThis is CancerLearning With National LeadersIn the NewsTreatmentClinicalHow Siteman is leading the way in personalized brain tumor treatmentIf you or a loved one have recently been diagnosed with a brain tumor, you likely feel a great deal of fear and have many questions. The brain is the epicenter of who we are,...Read The Full StoryTreatmentClinicalHow Siteman is leading the way in personalized brain tumor treatmentIf you or a loved one have recently been diagnosed with a brain tumor, you likely feel a great deal of fear and have many questions. The brain is the epicenter of who we are,...Read The Full StoryPhysician DirectoryClinical Trials SearchPatient ExperienceSiteman Psychology ServiceSurvivorshipCardio-OncologyLymphedema SurgeryNCI Cancer Information A to ZTreatment RolesCancer TypesCancer TypesBladderBrainBreastCervicalChildhood CancersColorectalYoung Onset ColorectalEsophagealGallbladderHead/NeckKidneyLeukemiaLiverLungLymphomaMultiple MyelomaMyelodysplastic Syndromes (MDS)OvarianPancreaticProstateSarcoma/Rare TumorsSkinStomachTesticularThyroidUterineThe Siteman ApproachThe Siteman ApproachMedical TherapyExpertise in Radiation OncologySurgeryGenetics and Hereditary CancerCancer ImagingImmunology and ImmunotherapyPathologyPatient and Family ServicesSpecialized ProgramsSpecialized ProgramsStem Cell Transplant and Cellular Therapies CenterGynecologic OncologyBrain Tumor CenterSarcomaVisitingNews/In the MediaSiteman Cancer Center expands proton therapy treatmentSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is expanding proton therapy for patients by adding the latest, most innovative technology to its S. Lee Kling Proton Therapy Center with the addition of...Read The Full StoryVisitingNews/In the MediaSiteman Cancer Center expands proton therapy treatmentSiteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is expanding proton therapy for patients by adding the latest, most innovative technology to its S. Lee Kling Proton Therapy Center with the addition of...Read The Full StoryPatient and Family ServicesWashington University Medical CampusWest CountySt. Charles CountySouth CountySiteman Kids at St. Louis Children’s HospitalNorth CountyIllinoisSiteman Cancer NetworkCancer Care ClinicBarnard Health and Cancer Information CenterPharmaciesPayment Information &＃038; AssistancePatient RightsPatient PrivacyPreventionPreventionSiteman explains what every woman should know about endometrial cancer risk, symptoms and screeningEndometrial cancer is the fourth most common cancer for women in the United States. It also accounts for approximately 4 percent of cancer deaths in women. However, because it is usually diagnosed early, it is...Read The Full StoryPreventionPreventionSiteman explains what every woman should know about endometrial cancer risk, symptoms and screeningEndometrial cancer is the fourth most common cancer for women in the United States. It also accounts for approximately 4 percent of cancer deaths in women. However, because it is usually diagnosed early, it is...Read The Full StoryYour Disease Risk®Preventing CancerRisk FactorsScreeningSmoking CessationMammographyGenetic CounselingCancer News in Context8IGHTWAYS® to Prevent CancerHealth DisparitiesCommunity Outreach and EngagementResearchResearchImmunity boosting treatment enhances CAR-T cell therapy for blood cancersAdvances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration...Read The Full StoryResearchResearchImmunity boosting treatment enhances CAR-T cell therapy for blood cancersAdvances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration...Read The Full StoryList of ResearchersSignificant Research AdvancesLearn About Clinical TrialsMembership InformationPlan to Enhance Diversity (PED)Research ProgramsFunding OpportunitiesTraining &＃038; EducationShared Resources (Cores)Resources for ResearchersSPORE in Pancreatic CancerSPORE in Endometrial CancerSPORE in LeukemiaCenter for Genome IntegrityCliniciansNews/In the Media$5.3 million grant supports research into lung cancer recurrenceResearchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after...Read The Full StoryCliniciansNews/In the Media$5.3 million grant supports research into lung cancer recurrenceResearchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after...Read The Full StoryPhysician ServicesEducational ProgramsGiveNews/In the MediaCouple honors physician with gift for distinguished professorshipEndowment will support leader in gynecologic oncology Financial adviser Elizabeth Mannen Berges lives each day with heightened gratitude for the basic components of a meaningful life—fulfilling work, caring relationships, and a sense of purpose. A...Read The Full StoryGiveNews/In the MediaCouple honors physician with gift for distinguished professorshipEndowment will support leader in gynecologic oncology Financial adviser Elizabeth Mannen Berges lives each day with heightened gratitude for the basic components of a meaningful life—fulfilling work, caring relationships, and a sense of purpose. A...Read The Full StorySiteman Advancement OfficeVolunteering and ContributingThe Foundation for Barnes-Jewish Hospital Request an Appointment Request an Appointment For help choosing a doctor or making an appointment, please complete our form or call us directly. (800) 600-3606 I am a: Patient / New Patient Caregiver Physician Back to All News Immunity boosting treatment enhances CAR-T cell therapy for blood cancers By Julia Evangelou Strait | June 13, 2022Washington University School of Medicine A study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting... A study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells. Shown are CAR-T cells infiltrating a lymphoma tumor in a mouse. Tumor cells are shown in blue, tumor-attacking CAR-T cells in green and immune cells called macrophages in red. Share Tweet Send Advances in cellular immunotherapy that spur genetically modified T cells to attack cancer cells have revolutionized the treatment of certain blood cancers. Six such CAR-T cell therapies are approved by the Food and Drug Administration to treat certain types of leukemia, lymphoma and multiple myeloma. Still, some patients’ tumors don’t respond well to these therapies, and many patients who do well initially later see their cancers return. Now, a new study by researchers at Washington University School of Medicine in St. Louis shows that additional treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of these genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells. The mouse study — published June 13 in the journal Nature Communications — suggests promise for a phase 1 clinical trial at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trial is investigating a long-acting genetically modified type of IL-7 in conjunction with CAR-T cells targeting CD19, a B cell antigen in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). Siteman is the coordinating center and one of four sites across the country participating in the trial. “Many researchers are trying different strategies to enhance the function of CAR-T cells in treating blood cancers,” said senior author John F. DiPersio, MD, PhD, the Virginia E. & Sam J. Golman Professor of Medicine and director of the Division of Oncology. “We’re interested in IL-7 because we know it is a major driver of T cell expansion. The body makes IL-7 naturally to ramp up the number of T cells when a person gets sick, for example. When we give a long-acting type of IL-7 to tumor-bearing immunodeficient mice soon after CAR-T cell treatment, we see a dramatic expansion of these CAR-T cells greater than ten-thousandfold compared to mice not receiving IL-7.  These CAR-T cells also persist longer and show dramatically increased anti-tumor activity.” CAR-T cells are manufactured using the body’s normal T cells, either from the patient or a donor. The CAR-T cells are genetically modified to specifically target a protein on the surface of the cancer cells. The targeting helps the CAR-T cells find the cancer cells, which are masters at evading immune attack. The therapy can be highly effective, but sometimes the CAR-T cells aren’t able to expand enough to kill all of the cancer, or they become overstimulated, “exhausting” their ability to function, resulting in their loss of anti-tumor effectiveness. With these problems in mind, the researchers — including first author Miriam Y. Kim, MD, an assistant professor of medicine, and co-senior author Matthew L. Cooper, PhD, an adjunct assistant professor of medicine — were interested in whether they could harness the body’s natural way of boosting T cell numbers to enhance the therapy. But natural IL-7 normally disappears from the body quickly. Therefore, DiPersio and his team tested a modified form of IL-7 that circulates in the body for weeks, making it much more effective at supporting the CAR-T cell expansion. Investigating two different models of B cell lymphoma in mice, the researchers showed that mice receiving CAR-T cells and long-acting IL-7 survived almost six times longer than mice receiving CAR-T cells alone. Mice treated with CAR-T cells alone survived for about one month after therapy. All mice that received long-acting IL-7 soon after the CAR-T cell treatment were still living at the end of an experimental time frame of 175 days. Further, tumor sizes in the mice that had received CAR-T cells and IL-7 were dramatically reduced, to the point of being undetectable in the majority of mice by day 35. “In mice that received the CAR-T cells alone, the disease is controlled briefly,” DiPersio said. “But by week three, the tumor starts to return. And by week four, they start to look like the control mice that didn’t receive any active therapy. But by adding long-acting IL-7, the numbers of CAR-T cells just explode, and those mice lived beyond the time frame we set for our experiment. Our study also suggests that it may be possible to fine-tune the expansion of the CAR-T cells by controlling the number of IL-7 doses that we give.” Washington University research laid the groundwork for using IL-7 to boost the immune system to treat disease, including its use with CAR-T cells. In addition, Richard S. Hotchkiss, MD, a professor of anesthesiology, of medicine and of surgery, and his team have studied IL-7 for its use in stimulating T cells to fight sepsis, a life-threatening response to infection. Research from the Brain Tumor Center at Siteman also has shown promise for the use of long-acting IL-7 to enhance T cells in treating glioblastoma, an aggressive brain cancer. Latest Posts New cell-based immunotherapy offered for melanoma 02/20/2024 Posted by Julia Evangelou Strait Confidence through Care: Finding Hope and Healing with Siteman 06/19/2024 Posted by Siteman Communications Pachynski Receives Scholar-Innovator Award 06/09/2024 Posted by Siteman Communications For Your Health – Eleven Tips for a Healthier Summer 06/05/2024 Posted by Dr. Graham A. Colditz View All News Contact 800-600-3606 Email Subscribe for Siteman Updates X-twitter Facebook Youtube Linkedin Instagram Careers Washington University Barnes-Jewish Hospital Locations Washington University Medical Campus West County St. Charles County South County North County Illinois Copyright © 2015 - 2024 All rights reserved.